Switch theme
Sign up to access all valuation multiples
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
2012
480
LTM Revenue $28.3M
LTM EBITDA -$164M
$449M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
uniQure has a last 12-month revenue (LTM) of $28.3M and a last 12-month EBITDA of -$164M.
In the most recent fiscal year, uniQure achieved revenue of $27.1M and an EBITDA of -$161M.
uniQure expects next 12-month revenue of XXX and NTM EBITDA of XXX
See uniQure valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $28.3M | XXX | $27.1M | XXX | XXX | XXX |
| Gross Profit | $15.6M | XXX | $8.8M | XXX | XXX | XXX |
| Gross Margin | 55% | XXX | 32% | XXX | XXX | XXX |
| EBITDA | -$164M | XXX | -$161M | XXX | XXX | XXX |
| EBITDA Margin | -579% | XXX | -593% | XXX | XXX | XXX |
| EBIT | -$176M | XXX | -$181M | XXX | XXX | XXX |
| EBIT Margin | -620% | XXX | -667% | XXX | XXX | XXX |
| Net Profit | -$217M | XXX | -$240M | XXX | XXX | XXX |
| Net Margin | -765% | XXX | -883% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, uniQure's stock price is $14.
uniQure has current market cap of $792M, and EV of $449M.
See uniQure trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $449M | $792M | XXX | XXX | XXX | XXX | $-4.33 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, uniQure has market cap of $792M and EV of $449M.
uniQure's trades at 16.6x EV/Revenue multiple, and -2.8x EV/EBITDA.
Equity research analysts estimate uniQure's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
uniQure has a P/E ratio of -3.7x.
See valuation multiples for uniQure and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $792M | XXX | $792M | XXX | XXX | XXX |
| EV (current) | $449M | XXX | $449M | XXX | XXX | XXX |
| EV/Revenue | 15.9x | XXX | 16.6x | XXX | XXX | XXX |
| EV/EBITDA | -2.7x | XXX | -2.8x | XXX | XXX | XXX |
| EV/EBIT | -2.6x | XXX | -2.5x | XXX | XXX | XXX |
| EV/Gross Profit | 28.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.7x | XXX | -3.3x | XXX | XXX | XXX |
| EV/FCF | -2.5x | XXX | -2.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialuniQure's last 12 month revenue growth is 64%
uniQure's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.4M for the same period.
uniQure's rule of 40 is -1534% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
uniQure's rule of X is -419% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for uniQure and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 64% | XXX | 60% | XXX | XXX | XXX |
| EBITDA Margin | -579% | XXX | -593% | XXX | XXX | XXX |
| EBITDA Growth | -11% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -1534% | XXX | -529% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -419% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 530% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 700% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
uniQure acquired XXX companies to date.
Last acquisition by uniQure was XXXXXXXX, XXXXX XXXXX XXXXXX . uniQure acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was uniQure founded? | uniQure was founded in 2012. |
| Where is uniQure headquartered? | uniQure is headquartered in United States of America. |
| How many employees does uniQure have? | As of today, uniQure has 480 employees. |
| Who is the CEO of uniQure? | uniQure's CEO is Mr. Matthew C. Kapusta. |
| Is uniQure publicy listed? | Yes, uniQure is a public company listed on NAS. |
| What is the stock symbol of uniQure? | uniQure trades under QURE ticker. |
| When did uniQure go public? | uniQure went public in 2014. |
| Who are competitors of uniQure? | Similar companies to uniQure include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of uniQure? | uniQure's current market cap is $792M |
| What is the current revenue of uniQure? | uniQure's last 12 months revenue is $28.3M. |
| What is the current revenue growth of uniQure? | uniQure revenue growth (NTM/LTM) is 64%. |
| What is the current EV/Revenue multiple of uniQure? | Current revenue multiple of uniQure is 15.9x. |
| Is uniQure profitable? | Yes, uniQure is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of uniQure? | uniQure's last 12 months EBITDA is -$164M. |
| What is uniQure's EBITDA margin? | uniQure's last 12 months EBITDA margin is -579%. |
| What is the current EV/EBITDA multiple of uniQure? | Current EBITDA multiple of uniQure is -2.7x. |
| What is the current FCF of uniQure? | uniQure's last 12 months FCF is -$176M. |
| What is uniQure's FCF margin? | uniQure's last 12 months FCF margin is -623%. |
| What is the current EV/FCF multiple of uniQure? | Current FCF multiple of uniQure is -2.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
